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Gonadotropin releasing hormone agonists (GnRHas) have been found to impair memory in adults,
so the study by Wojniusz et al. (2016) on the possible cognitive effects of these drugs on children
treated for idiopathic central precocious puberty (CPP) represents an important contribution to
research in this area. Recent findings that GnRHas increase depression symptoms (Macoveanu
et al., 2016) and slow reaction time (Stenbæk et al., 2016) in healthy women, and reduce long-
term spatial memory in sheep (Hough et al., 2017) underline the importance of the research
that Wojniusz et al. (2016) have undertaken. However, their reassuring statement in the abstract
that girls undergoing GnRHa treatment for CPP and controls “showed very similar scores with
regard to cognitive performance” and their conclusion that “GnRHa treated girls do not differ
in their cognitive functioning ... from the same age peers” (Wojniusz et al., 2016) may be overly
optimistic. These statements minimize the fairly substantial difference found in IQ scores and may
also overemphasize its lack of statistical significance, as given the small number of participants
in the study statistical significance has a high threshold. The statements should be qualified to
indicate that the research has, in fact, reinforced concerns over the impact of GnRHas on cognitive
performance in children.
Girls treated for CPP with triptorelin acetate were tested with the short form Wechsler
Intelligence Scale for Children III. It was found that the girls had a mean IQ of 94, as against a
mean IQ of 102 for the matched control group (Wojniusz et al., 2016). These IQ estimations are
presented as standardized IQ scores, which places a girl scoring 102 at the 55th percentile, and a
girl scoring of 94 at the 34th percentile. It is questionable whether scores that indicate a percentile
gap of this size can be described as “very similar.” The 8 point gap is not statistically significant
(p= 0.09) but, as the authors point out, this may be a function of the small number of participants
(15 treated girls, 15 controls).
The authors contend that despite the small number of participants the results can—probably—
be relied on to indicate that if GnRHas do cause a decline in IQ, this decline will be under 1
standard deviation (SD), which “represents a boundary of what is a clinically interesting difference”
Hayes Precocious Puberty Treatment and IQ
(Wojniusz et al., 2016). The contention that a decline only
becomes clinically interesting if it is of at least 1 standard
deviation is unconvincing. Any findings which indicate that
GnRHas cause a decline, even a modest decline, in IQ are likely
to be of considerable interest to patients and their parents. It is a
factor that they may well want to consider in deciding whether or
not to take the drug. They may, for example, wish to consider
the possible effect of GnRHas on a child’s school and exam
performance. In this respect it can be noted that 2 of the treated
girls had been held back a year at school. Given their advanced
physical maturity, children with precocious puberty may find it
particularly uncomfortable to be put in a class where they are a
year older than their class mates. If GnRHa treatment does cause
a reduction in IQ, this may contribute to the decision to place a
child in a lower age year group. Certainly, treatment that has a
deleterious effect on IQ will do nothing to help children who are
academically behind to catch up.
The question of whether a drop in IQ of around 8 points has
clinical significance must also be considered in the context of
the uncertain benefits of GnRHa treatment for CPP. The ability
of GnRHas to increase final height has not been confirmed by
randomized controlled trials (Bouvattier et al., 1999; Cassio et al.,
1999). Where girls with CPP experience psychosocial difficulties,
providing support rather than drugs may be themost appropriate
response (Hayes, 2016).
The findings of Wojniusz et al. (2016) can be compared with
those of a 2001 study in which 25 children treated for early
puberty with triptorelin acetate were tested with the short form
Wechsler Intelligence Scale for Children (Mul et al., 2001). In
this longitudinal study, children took the IQ test before treatment
and again after 2 years of treatment. It was found that their IQ
dropped 7 points from 100 to 93. With 25 treated participants,
this 7 point drop was significant (p = 0.002). In both studies the
difference in the performance element of the test was greater than
in the verbal element. The similarities between the findings of
these two studies strengthens their reliability and increases the
possibility that GnRHa treatment may have an adverse impact
on cognitive functioning in children. This makes it yet more
important for further research to be carried out into the effects
GnRHas may have on cognitive performance in children.
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